Ticagrelor + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
Trial Timeline
Sep 1, 2011 → Nov 1, 2013
NCT ID
NCT01347580About Ticagrelor + Placebo
Ticagrelor + Placebo is a approved stage product being developed by AstraZeneca for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT01347580. Target conditions include Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03615924 | Phase 3 | Terminated |
| NCT03354429 | Phase 3 | Completed |
| NCT02482298 | Phase 2 | Completed |
| NCT02352402 | Phase 3 | UNKNOWN |
| NCT02110303 | Phase 2/3 | Completed |
| NCT02335099 | Phase 1/2 | Completed |
| NCT01998399 | Phase 2 | Terminated |
| NCT02070653 | Phase 2 | Completed |
| NCT01347580 | Approved | Completed |
Competing Products
20 competing products in Myocardial Infarction